Deals in Depth: October 2008
Executive SummaryOctober 2008 dealmaking highlights: China Medical's purchase of the HPV-DNA biosensor chip and SPR technology from Molecular Diagnostics Technologies for $345 million was the leading alliance in terms of $ value. Eli Lilly emerged as the mystery bidder for ImClone, defeating BMS and signing a definitive agreement to buy the biotech for $6.5 billion. In October no FOPOs or IPOs were completed in either industry. Private placements, mostly from early- and late-VC rounds, in biopharmas decreased 31% from last month to $358 million while investments in medical devices were up 1.5x to $296 million.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.